ASCLETIS-B (01672) surged over 5% today, rising 5.02% to HK$10.88 with trading volume reaching HK$92.59 million as of press time.

The pharmaceutical company announced this morning that it presented results from its ASC30 oral small molecule GLP-1R agonist 28-day multiple ascending dose study at the 61st Annual Meeting of the European Association for the Study of Diabetes held in Vienna, Austria on September 16, 2025.

The once-daily oral ASC30 tablets demonstrated significant efficacy, with placebo-adjusted mean weight reduction from baseline reaching up to 6.5% after 28 days of treatment. The superior efficacy of ASC30 tablets was attributed to higher oral drug exposure levels. The treatment showed favorable safety and tolerability profiles, with only mild to moderate gastrointestinal adverse events reported. Notably, no vomiting occurred in multiple ascending dose cohort 1, which employed a weekly titration strategy from 2mg to 5mg.

Soochow Securities recently highlighted that the company has multiple catalysts lined up for the second half of the year, with several important clinical data readouts approaching. Based on clinical trial progress and company announcements, the brokerage expects ASC30 oral Phase II, ASC47 Phase I, and ASC50 Phase I topline data to be released in Q4 2025, while ASC30 subcutaneous injection Phase II topline data is anticipated in Q1 2026.

Additionally, the company expects to submit INDs for 2-3 new pipeline programs to the FDA within the next 6-9 months, including dual-target peptide weight management programs.